Optimal predictive probability designs for randomized biomarker-guided oncology trials by Emily C. Zabor, Alexander M. Kaizer, Nathan A. Pennell, Brian P. Hobbs

Get full text

Novel radiogenomics approach to predict and characterize pneumonitis in stage III NSCLC by Lukas Delasos, Mohammadhadi Khorrami, Vidya S. Viswanathan, Khalid Jazieh, Yifu Ding, Pushkar Mutha, Kevin Stephans, Amit Gupta, Nathan A. Pennell, Pradnya D. Patil, Kristin Higgins, Anant Madabhushi

Get full text

Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab by Amit Gupta, Pingfu Fu, Nathan A Pennell, Mohamed Gad, Mohammadhadi Khorrami, Anant Madabhushi, Anas Saad, Pradnya Patil, Khalid Jazieh, Vidya Sankar Viswanathan, Prabhakar Rajiah, Charles J Nock, Michael Gilkey

Get full text

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC by Christopher A. Lemmon, MD, Gregory M.M. Videtic, MDCM, Sudish Murthy, MD, PhD, Kevin L. Stephans, MD, Marc Shapiro, MD, Usman Ahmad, MD, Daniel Raymond, MD, Vamsidhar Velcheti, MD, Alejandro Bribriesco, MD, Xuefei Jia, MS, James Stevenson, MD, Nathan A. Pennell, MD, PhD

Get full text